Checked
Puma Biotechnology, Inc.
Nasdaq: PBYI · Pharmaceutical Preparations · Los Angeles, CA
- Revenue
- $228.4M
- -0.9% vs. prior year
- Net income
- $31.11M
- 13.6% net margin
- Total assets
- $216.3M
- Diluted EPS
- $0.61
Company details
As reported to the SEC
- SEC CIK
- 1401667
- Stock
- Nasdaq: PBYI
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- 10880 Wilshire Blvd., Suite 1700, Los Angeles, CA
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Accelerated filer, Smaller reporting company
- Phone
- (424) 248-6500
- Employer ID (EIN)
- 77-0683487
- Last annual report
- 02/26/2026
- Last quarterly report
- 08/06/2026
Formerly: INNOVATIVE ACQUISITIONS CORP (until 10/04/2011)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $228.4M | $230.5M | $235.6M | $228M | $253.2M |
| Operating income | $37.3M | $30.97M | $32.64M | $23.72M | $1.29M |
| Net income | $31.11M | $30.28M | $21.59M | $2K | -$29.13M |
| Diluted earnings per share | $0.61 | $0.62 | $0.45 | $0.00 | -$0.72 |
| Research and development | $62.07M | $54.94M | $50.38M | $52.24M | $71.87M |
| Total assets | $216.3M | $213.3M | $230.5M | $222.1M | $226.6M |
| Total liabilities | $85.96M | $121.2M | $177.1M | $200.5M | $229M |
| Shareholders' equity | $130.3M | $92.13M | $53.44M | $21.61M | -$2.45M |
| Cash and cash equivalents | $29.64M | $69.22M | $84.58M | $76.2M | $63.13M |
| Long-term debt | $0 | $21.72M | $65.66M | $98.31M | $97.09M |
| Cash from operations | $41.8M | $38.92M | $27.01M | -$15.83M | $20.65M |
| Capital expenditures | $71K | $56K | $140K | $0 | $0 |
Federal and state records filed under the name Puma Biotechnology, Inc.
Matched by the company name and by the subsidiary names it lists in SEC filings and other public records, after removing endings like Inc., Corp. and Holdings. Records marked Subsidiary were filed under a subsidiary name. A subsidiary that is not listed in those records is not included, and an unrelated business with the same name can appear.
Work visa sponsorship
Certified H-1B and PERM green card filings with the Department of Labor
| Employer on filing | H-1B | PERM |
|---|---|---|
| Puma Biotechnology, IncLos Angeles, CA | 4 | 0 |
Subsidiaries
1 company that Puma Biotechnology, Inc. owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| Puma Biotechnology B.V. | SEC 10-K |
Recent filings
139 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
| Form | Filed | Period |
|---|---|---|
| SCHEDULE 13D/AOwnership report (5% holder, active, amended) | 10/06/2026 | None |
| 10-QQuarterly report | 08/06/2026 | 06/30/2026 |
| 8-KResults of operations | 08/06/2026 | 08/06/2026 |
| 8-KShareholder vote results | 06/16/2026 | 06/11/2026 |
| 10-QQuarterly report | 05/07/2026 | 03/31/2026 |
| 8-KResults of operations | 05/07/2026 | 05/07/2026 |
| DEFA14AAdditional proxy materials | 04/28/2026 | None |
| ARSAnnual report to shareholders | 04/28/2026 | 12/31/2025 |
| DEF 14AProxy statement | 04/28/2026 | 06/11/2026 |
| PRE 14APreliminary proxy statement | 04/07/2026 | 06/11/2026 |
| SCHEDULE 13G/AOwnership report (5% holder, passive, amended) | 03/27/2026 | None |
| 10-KAnnual report | 02/26/2026 | 12/31/2025 |
| 8-KResults of operations | 02/26/2026 | 02/26/2026 |
| 10-QQuarterly report | 11/06/2025 | 09/30/2025 |
| 8-KResults of operations | 11/06/2025 | 11/06/2025 |
| 10-QQuarterly report | 08/07/2025 | 06/30/2025 |
| 8-KResults of operations | 08/07/2025 | 08/07/2025 |
| 10-Q/AQuarterly report (amended) | 08/07/2025 | 03/31/2025 |
| 8-KBylaws or fiscal year change | 06/24/2025 | 06/19/2025 |
| 8-KShareholder vote results | 06/13/2025 | 06/11/2025 |
36 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Puma Biotechnology, Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Puma Biotechnology, Inc.'s CIK number?
- Puma Biotechnology, Inc.'s SEC Central Index Key (CIK) is 1401667.
- What is Puma Biotechnology, Inc.'s stock ticker?
- Puma Biotechnology, Inc. trades as Nasdaq: PBYI.
- What was Puma Biotechnology, Inc.'s revenue?
- Puma Biotechnology, Inc. reported revenue of $228.4M for the fiscal year ended Dec 31, 2025, -0.9% from the year before.
- When does Puma Biotechnology, Inc.'s fiscal year end?
- Puma Biotechnology, Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Puma Biotechnology, Inc. headquartered?
- Puma Biotechnology, Inc.'s principal executive office on file with the SEC is in Los Angeles, CA.
- What companies does Puma Biotechnology, Inc. own?
- Puma Biotechnology, Inc. lists 1 subsidiary in its SEC filings and other public records, including Puma Biotechnology B.V.
- Does Puma Biotechnology, Inc. sponsor H-1B visas?
- Department of Labor records show 4 certified H-1B filings and 0 certified PERM filings under the name Puma Biotechnology, Inc.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026